Financings/Collaborations In Brief: Sequus
Executive Summary
Sequus: Public offering of 3.9 mil. shares of common stock at $11 per share announced Oct. 25. The offering is co-managed by Robertson Stephens & Co., Read & Co., Oppenheimer and Punk, Ziegel & Knoell; they have an option to purchase an additional 585,000 shares to cover over-allotments. Menlo Park, Calif.-based Sequus' Doxil liposomal doxorubicin is "approvable" at FDA as second-line therapy for AIDS-related Kaposi's sarcoma...